Основная статистика
| LEI | 529900IVC72YPFA25M37 |
| CIK | 1607678 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Viking Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 19, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 Viking Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 19, 2025 |
Exhibit 99.1 Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK27 |
|
| July 23, 2025 |
Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 3 VANQUISH Registration Trials Underway for VK2735 in Obesity • Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25 • Continued Progress with Amylin Program; IND Planned 4Q25 • Strong Quarter-End Cas |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 Viking Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Viking Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 24, 2025 |
Exhibit 10.1 ***Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** STRATEGIC MANUFACTURING AND SUPPLY AGREEMENT This STRATEGIC MANUFACTURING AND |
|
| April 24, 2025 |
Exhibit 10.3 ***Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** MANUFACTURING AND SUPPLY (Drug Product) AGREEMENT This MANUFACTURING AND SUPPL |
|
| April 24, 2025 |
Exhibit 10.2 ***Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** PREPAYMENT AGREEMENT between VIKING THERAPEUTICS IRELAND LIMITED as Purchaser, |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THE |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 (April 18, 2025) Viking Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorpor |
|
| April 23, 2025 |
Letter from Marcum LLP to the Securities and Exchange Commission, dated April 23, 2025. Exhibit 16.1 April 23, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Viking Therapeutics, Inc. under Item 4.01 of its Form 8-K dated April 23, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Viking Therapeutics, Inc. co |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Viking Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 23, 2025 |
Exhibit 99.1 Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25 • Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25 • Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735 • |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 8, 2025 |
Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego, CA 92121 858-704-4660 April 8, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Eric Atallah Kevin Kuhar Re: Viking Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-37355 Ladies and Gentlemen: This letter |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 11, 2025 |
Exhibit 99.1 Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply Provides Annual Capa |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Viking Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 26, 2025 |
List of Subsidiaries of Viking Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Viking Therapeutics, Inc. Viking Therapeutics Ireland Limited (Ireland) Viking Therapeutics, PTY LTD (Australia) |
|
| February 26, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.12 Viking Therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each non-employee member of the board of directors (the “Board”) of Viking Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation for his or her service on the Board as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation d |
|
| February 26, 2025 |
Exhibit 10.11 EMPLOYMENT AGREEMENT Employee agrees to the terms and conditions of employment with Viking Therapeutics, Inc. ("Company") set forth in this Employment Agreement ("Agreement"), effective as of December 30, 2016 ("Effective Date"). 1. Employment Terms. (a) Employment Period. The Company shall employ Employee, and Employee hereby accepts employment with the Company, upon the terms and c |
|
| February 26, 2025 |
Exhibit 10.16 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** VIKING THERAPEUTICS, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”) is made a |
|
| February 26, 2025 |
Exhibit 19 VIKING THERAPEUTICS, INC. INSIDER TRADING POLICY And Guidelines with Respect to Certain Transactions in Company Securities This Insider Trading Policy (this “Policy”) provides guidelines to employees, officers and directors of Viking Therapeutics, Inc. and each of its subsidiaries, branches, representative offices and similar entities (collectively, the “Company”) with respect to transa |
|
| February 26, 2025 |
Exhibit 10.10 EMPLOYMENT AGREEMENT Employee agrees to the terms and conditions of employment with Viking Therapeutics, Inc. ("Company") set forth in this Employment Agreement ("Agreement"), effective as of May 21, 2015 ("Effective Date"). 1. Employment Terms. (a) Employment Period. The Company shall employ Employee, and Employee hereby accepts employment with the Company, upon the terms and condit |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeu |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of I |
|
| February 5, 2025 |
Exhibit 99.1 Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 • Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway • Strong Year-End Cash Position of $903 Million SAN DIEGO, February 5, |
|
| November 14, 2024 |
VKTX / Viking Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) VIKING THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 4, 2024 |
Exhibit 99.1 Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Dura |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of I |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING |
|
| October 23, 2024 |
Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 • Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 • Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentati |
|
| October 18, 2024 |
VKTX / Viking Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 VikingTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIKING THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92686J106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| July 24, 2024 |
Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 • Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 • Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Plan |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of Inco |
|
| July 24, 2024 |
Exhibit 10.3 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** Second Amendment To Master License Agreement This Second Amendment to Master License Agreement (this “Amendment”) is dated |
|
| July 24, 2024 |
Exhibit 10.1 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** MASTER LICENSE AGREEMENT Dated May 21, 2014 by and between Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, |
|
| July 24, 2024 |
Exhibit 10.2 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** First Amendment To Master License Agreement This First Amendment to Master License Agreement (this “Amendment”) is dated as |
|
| June 4, 2024 |
Exhibit 99.1 Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosi |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 22, 2024 |
Exhibit 4.3 Viking Therapeutics, Inc. Stock Option Grant Notice (2024 Equity Incentive Plan) Viking Therapeutics, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein an |
|
| May 22, 2024 |
2024 Employee Stock Purchase Plan. Exhibit 4.6 Viking Therapeutics, Inc. 2024 Employee Stock Purchase Plan Adopted by the Board Of Directors: March 15, 2024 Approved by the Stockholders: May 21, 2024 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a seri |
|
| May 22, 2024 |
Exhibit 4.4 Viking Therapeutics, Inc. RSU Award Grant Notice (2024 Equity Incentive Plan) Viking Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Comp |
|
| May 22, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 22, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 22, 2024 |
Exhibit 4.5 Viking Therapeutics, Inc. Restricted Stock Award Grant Notice (2024 Equity Incentive Plan) Viking Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of shares of Common Stock on the terms set forth below in consideration of your services (the “Restricted Stock”). The grant of the Restricted Stock (the “Restricted Stock Award”) is subject to all of the |
|
| May 22, 2024 |
Exhibit 4.2 Viking Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: March 15, 2024 Approved by the Stockholders: May 21, 2024 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company a |
|
| May 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viking Therapeutics, Inc. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THE |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of Inc |
|
| April 24, 2024 |
Exhibit 99.1 Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From Baseline) at 13 Weeks; Shown to be Safe and Well-Tolerated • Results From Phase 1 Trial of Oral VK273 |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 26, 2024 |
Exhibit 99.1 Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Sc |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 4, 2024 |
Exhibit 99.1 Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, CA – March 4, 2024 – Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the clo |
|
| March 1, 2024 |
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock Exhibit 99.1 Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock SAN DIEGO, CA – February 28, 2024 – Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 6,471,000 shares |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Viking Therapeutics, Inc. |
|
| March 1, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-273460 PROSPECTUS SUPPLEMENT (To Prospectus dated July 26, 2023) 6,471,000 Shares Common Stock We are offering 6,471,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market under the symbol “VKTX.” The last reported sale price of our common stock on the Nasdaq Capital Market on February 28, 2024 |
|
| March 1, 2024 |
Exhibit 1.1 6,471,000 Shares VIKING THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT February 28, 2024 February 28, 2024 Morgan Stanley & Co. LLC Leerink Partners LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Leerink Partners LLC 255 California Street, 12th Floor San Francisco, California 94111 Ladies and Gentlemen: Viking Therapeut |
|
| March 1, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 27, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-273460 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities, a |
|
| February 27, 2024 |
Exhibit 99.1 Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After |
|
| February 14, 2024 |
VKTX / Viking Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) VIKING THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 |
|
| February 13, 2024 |
VKTX / Viking Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Viking Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 92686J106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| February 7, 2024 |
Exhibit 99.1 Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Results for Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Expected in 1Q24 • Histology Results for Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 1H24 • Results for Pha |
|
| February 7, 2024 |
Non-Employee Director Compensation Policy. Exhibit 10.11 Viking Therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each non-employee member of the board of directors (the “Board”) of Viking Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation for his or her service on the Board as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation d |
|
| February 7, 2024 |
As filed with the Securities and Exchange Commission on February 7, 2024 As filed with the Securities and Exchange Commission on February 7, 2024 Registration No. |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2024 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of I |
|
| February 7, 2024 |
Viking Therapeutics, Inc. Clawback Policy Exhibit 97 Viking Therapeutics, Inc. Clawback Policy The Board of Directors (the “Board”) of Viking Therapeutics, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeu |
|
| February 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viking Therapeutics, Inc. |
|
| January 12, 2024 |
VKTX / Viking Therapeutics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) VIKING THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 92686J106 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate |
|
| November 2, 2023 |
VKTX / Viking Therapeutics Inc / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* VIKING THERAPEUTICS, INC. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) Oct |
|
| October 25, 2023 |
Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Fully Enrolled; Results Expected 1H24 • Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Ongoing; Histology Results Expected 1H24 • Phase 1 Trial of O |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of I |
|
| July 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of Inco |
|
| July 26, 2023 |
Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Reported Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH, Showing up to 55% Median Liver Fat Reduction; 52 Week Biopsy Results Expected 1H24 • Phase 2 Study of Dual GLP-1/GIP Agonist VK2 |
|
| July 26, 2023 |
Exhibit 10.1 AMENDMENT NO. 1 TO AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT July 26, 2023 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 TRUIST SECURITIES, INC. 3333 Peachtree Road NE, 11th Floor Atlanta, Georgia 30326 H.C. WAINWRIGHT & CO., LLC 430 Park Avenue New York, NY 10022 BTIG, LLC 600 Montgomery Street San Francisco, CA 94111 Ladies and G |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| July 26, 2023 |
As filed with the Securities and Exchange Commission on July 26, 2023 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No. |
|
| July 26, 2023 |
Form of Indenture, between the Registrant and one or more trustees to be named Exhibit 4.2 Viking Therapeutics, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE.............. 1 Section 1.1. Definitions.............................................................................................. 1 Section 1.2. Other Definitions................................................................................ |
|
| July 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Viking Therapeutics, Inc. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VIKING THERAPEUTICS, INC., a Delaware corporation SECTION 1. OFFICES The principal office of Viking Therapeutics, Inc., a Delaware corporation (the “Corporation”), shall be located at the principal place of business or such other place as the Board of Directors of the Corporation (the “Board”) may designate. The Corporation may have such other offices, ei |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of Inc |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THE |
|
| April 26, 2023 |
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p. |
|
| April 17, 2023 |
PRELIMINARY COPY DATED APRIL 17, 2023 – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 3, 2023 |
Exhibit 99.1 Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, CA – April 3, 2023 – Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing o |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 31, 2023 |
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock Exhibit 99.1 Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock SAN DIEGO, CA – March 29, 2023 – Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 17,242,000 shares of |
|
| March 31, 2023 |
Exhibit 1.1 VIKING THERAPEUTICS, INC. Common Stock, par value $0.00001 per share Underwriting Agreement March 29, 2023 William Blair & Company, L.L.C. As representative of the several Underwriters named in Schedule I hereto, c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Viking Therapeutics, Inc., a Delaware corporation (the “Company”), |
|
| March 31, 2023 |
17,242,000 Shares Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-258231 PROSPECTUS SUPPLEMENT (To Prospectus dated August 11, 2021) 17,242,000 Shares Common Stock We are offering 17,242,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market under the symbol “VKTX.” On March 28, 2023, the closing price of our common stock on the Nasdaq Capital Market was $15.4 |
|
| March 30, 2023 |
VKTX / Viking Therapeutics Inc / LIGAND PHARMACEUTICALS INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Viking Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) Ligand Pharmaceuticals Incorporated 3911 Sorrento Valley Boulevard, Suite 110 San Diego, CA 92121 (858) |
|
| March 29, 2023 |
Subject to Completion, Dated March 29, 2023 Filed pursuant to Rule 424(b)(5) Registration No. 333-258231 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we |
|
| March 28, 2023 |
Exhibit 99.1 Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 Up to 6.0% Placebo-Adjusted Mean Weight Loss (7.8% From Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study Phase 2 Trial in Obesity Planned for Mid-2023 SAN DIEGO, CA – March 28, 2023 – Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 28, 2023 |
Exhibit 99.1 Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 Expands Potential Opportunities for VK2735 with Highly Differentiated Dosing Option Data Anticipated in 2H2023 SAN DIEGO, CA – March 28, 2023 – Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the devel |
|
| February 14, 2023 |
VKTX / Viking Therapeutics Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeu |
|
| February 10, 2023 |
Exhibit 4.2 Description of Securities of Viking Therapeutics, Inc. The authorized capital stock of Viking Therapeutics, Inc., a Delaware corporation (the “Company”), consists of: • 300,000,000 shares of common stock, $0.00001 par value (“Common Stock”); and • 10,000,000 shares of preferred stock, $0.00001 par value (“Preferred Stock”). Common Stock • Dividend rights. Subject to preferences that ma |
|
| February 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viking Therapeutics, Inc. |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 9, 2023 |
EX-99.1 2 d461604dex991.htm EX-99.1 Exhibit 99.1 INFORMATION REGARDING THE DIRECTOR AND EXECUTIVE OFFICERS OF LIGAND PHARMACEUTICALS INCORPORATED AND METABASIS THERAPEUTICS, INC. The names and the principal occupations of the current directors and executive officers of Ligand Pharmaceuticals Incorporated (“Ligand”) are set forth below. The business address of each of the individuals named below is |
|
| February 9, 2023 |
VKTX / Viking Therapeutics Inc / LIGAND PHARMACEUTICALS INC - SC 13D/A Activist Investment SC 13D/A 1 d461604dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Viking Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) Ligand Pharmaceuticals Incorporated 3911 Sorrento Valley Boulevard, Suite |
|
| February 8, 2023 |
Exhibit 99.1 Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Data from Three Clinical Programs Expected in 2023 • Enrollment Completed in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in 2Q 2023 • Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Continues; Data Expec |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2023 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of I |
|
| January 3, 2023 |
VKTX / Viking Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 VIKING THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 92686J106 (CUSIP Number) DECEMBER 23, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING |
|
| October 26, 2022 |
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Company Positioned to Announce Data from Three Clinical Programs in 2023 • VK2809 Phase 2b VOYAGE Study On Track to Complete Enrollment in Q4 2022; Data Expected in 1H 2023 • Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Continues to Enroll |
|
| July 27, 2022 |
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today ? Clinical Data From Three Programs Anticipated in Next Twelve Months ? VK2809 Phase 2b VOYAGE Study Advancing; Completion of Enrollment Expected in 4Q 2022 ? Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Initial Results Expected by |
|
| July 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| May 26, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2022 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 27, 2022 |
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today ? Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH Expected in 2H22 ? Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Results Expected by Year-End ? Quarter-end Cash Balance of $185M Provides Runway |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THE |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2022 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| February 14, 2022 |
VKTX / Viking Therapeutics Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeu |
|
| February 9, 2022 |
As filed with the Securities and Exchange Commission on February 9, 2022 As filed with the Securities and Exchange Commission on February 9, 2022 Registration No. |
|
| February 9, 2022 |
Description of Registrant’s Securities Exhibit 4.5 Description of Securities of Viking Therapeutics, Inc. The authorized capital stock of Viking Therapeutics, Inc., a Delaware corporation (the ?Company?), consists of: ? 300,000,000 shares of common stock, $0.00001 par value (?Common Stock?); and ? 10,000,000 shares of preferred stock, $0.00001 par value (?Preferred Stock?). Common Stock ? Dividend rights. Subject to preferences that ma |
|
| February 9, 2022 |
List of Subsidiaries of Viking Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Viking Therapeutics, Inc. Viking Therapeutics, PTY LTD (Australia) LEGALUSW # 111055664.1 |
|
| February 9, 2022 |
Exhibit 99.1 Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today ? Data From Three Clinical Programs Expected in the Next 12-18 Months ? Enrollment Continuing in Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH ? Phase 1 SAD/MAD Trial of Dual GLP-1/GIP Agonist VK2735 Ongoing ? |
|
| February 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2022 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction (Commission (IRS Employer of I |
|
| February 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Viking Therapeutics, Inc. |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING |
|
| November 3, 2021 |
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today ? Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Proceeding ? Phase 1b Proof-of-Concept Trial Evaluating VK0214 in X-ALD Patients Underway ? Data From New Program Evaluating Novel Dual Agonists for Metabolic Disorders Presen |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2021 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 11, 2021 |
Viking Therapeutics, Inc. Up to $125,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-258231 PROSPECTUS Viking Therapeutics, Inc. Up to $125,000,000 Common Stock We have entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, Truist Securities, Inc., or Truist, and H.C. Wainwright & Co., LLC, or Wainwright, each of whom we refer to as an Age |
|
| August 5, 2021 |
12340 El Camino Real, Suite 250 San Diego, CA 92130 12340 El Camino Real, Suite 250 San Diego, CA 92130 August 5, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jessica Ansart 100 F Street, N. |
|
| July 28, 2021 |
As filed with the Securities and Exchange Commission on July 28, 2021 As filed with the Securities and Exchange Commission on July 28, 2021 Registration No. |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2021 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| July 28, 2021 |
Exhibit 1.2 Execution Version VIKING THERAPEUTICS, INC. Common Stock ($0.00001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT July 28, 2021 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 TRUIST SECURITIES, INC. 3333 Peachtree Road NE, 11th Floor Atlanta, Georgia 30326 H.C. WAINWRIGHT & CO., LLC 430 Park Avenue New York, NY 10022 |
|
| July 28, 2021 |
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today ? Enrollment Continues in Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH ? Phase 1 Study Evaluating VK0214 Achieves Primary and Secondary Objectives; Phase 1b Proof-of-Concept Trial in X-ALD Patients Underway ? Quarter-End |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2021 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 28, 2021 |
Form of Indenture, between the Registrant and one or more trustees to be named Exhibit 4.6 VIKING THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities Table of Contents Page Article 1 DEFINITIONS1 Section 1.01 Definitions of Terms1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES5 Section 2.01 Designation and Terms of Securities5 Section 2.02 Form of Securities and Trustee?s Certificate8 Section 2 |
|
| May 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2021 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2021 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THE |
|
| April 28, 2021 |
Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today ? U.S. and European Sites Continue to Enroll Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH ? Phase 1 Study Evaluating VK0214 in Healthy Volunteers Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-202 |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 8, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 17, 2021 |
As filed with the Securities and Exchange Commission on February 17, 2021 Registration No. |
|
| February 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2021 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 17, 2021 |
Description of Registrant’s Securities Exhibit 4.5 Description of Securities of Viking Therapeutics, Inc. The authorized capital stock of Viking Therapeutics, Inc., a Delaware corporation (the ?Company?), consists of: ? 300,000,000 shares of common stock, $0.00001 par value (?Common Stock?); and ? 10,000,000 shares of preferred stock, $0.00001 par value (?Preferred Stock?). Common Stock ? Dividend rights. Subject to preferences that ma |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeu |
|
| February 17, 2021 |
Exhibit 99.1 Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll • Phase 1 Trial Evaluating VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021 • Balance Sheet Remains Stron |
|
| February 16, 2021 |
SC 13G/A 1 arrowmark-vktx123120a3.htm 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* VIKING THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this State |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2021 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2020 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING |
|
| October 28, 2020 |
Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Ongoing • Phase 1 Trial Evaluating VK0214 for the Treatment of X-ALD Underway • Balance Sheet Remains Strong; Quarter-End Cash Approximately $255 Million SAN DIEGO, October 28 |
|
| August 28, 2020 |
EX-99.1 Exhibit 99.1 INFORMATION REGARDING THE DIRECTOR AND EXECUTIVE OFFICERS OF LIGAND PHARMACEUTICALS INCORPORATED AND METABASIS THERAPEUTICS, INC. The names and the principal occupations of the current directors and executive officers of Ligand Pharmaceuticals Incorporated (“Ligand”) are set forth below. The business address of each of the individuals named below is 3911 Sorrento Valley Boulev |
|
| August 28, 2020 |
VKTX / Viking Therapeutics, Inc. / LIGAND PHARMACEUTICALS INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Viking Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) Ligand Pharmaceuticals Incorporated 3911 Sorrento Valley Boulevard, Suite 110 San Diego, CA 92121 (858) |
|
| July 29, 2020 |
Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL • IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020 • Balance Sheet Remains Strong; Quarter- |
|
| July 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| July 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2020 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 21, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2020 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 20, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 30, 2020 |
Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH • New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL • IND Filing for VK0214 in X-ALD on Track for Mid-Year • Balance Sheet Remains Strong, Quarter-End Cash Appr |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THE |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2020 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 6, 2020 |
VKTX / Viking Therapeutics, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, d.c. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 6, 2020 |
VKTX / Viking Therapeutics, Inc. DEFA14A - - DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2020 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 26, 2020 |
Description of Registrant’s Securities Exhibit 4.5 Description of Securities of Viking Therapeutics, Inc. The authorized capital stock of Viking Therapeutics, Inc., a Delaware corporation (the “Company”), consists of: • 300,000,000 shares of common stock, $0.00001 par value (“Common Stock”); and • 10,000,000 shares of preferred stock, $0.00001 par value (“Preferred Stock”). Common Stock • Dividend rights. Subject to preferences that ma |
|
| February 26, 2020 |
VKTX / Viking Therapeutics, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeu |
|
| February 26, 2020 |
As filed with the Securities and Exchange Commission on February 26, 2020 As filed with the Securities and Exchange Commission on February 26, 2020 Registration No. |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 5, 2019 |
VKTX / Viking Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2019 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 5, 2019 |
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 8:30 a.m. ET today • IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH • Clinical Development of VK0214 for X-ALD Expected to Begin 1H20 • Balance Sheet Remains Strong with Approximately $290 Million in Cash SAN DIEGO, November 5, 2019 |
|
| October 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 1, 2019 |
Exhibit 10.1 VIKING THERAPEUTICS, INC. Common Stock ($0.00001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT August 1, 2019 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 OPPENHEIMER & CO. INC. 85 Broad Street, 26th Floor New York, NY 10004 Ladies and Gentlemen: Viking Therapeutics, Inc., a Delaware corporation (the “Company”), p |
|
| August 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 vktx-8k20190801.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2019 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdictio |
|
| August 1, 2019 |
Viking Therapeutics, Inc. Up to $75,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226133 PROSPECTUS SUPPLEMENT (To Prospectus dated July 19, 2018) Viking Therapeutics, Inc. Up to $75,000,000 Common Stock We have entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, and Oppenheimer & Co. Inc., or Oppenheimer, each of whom we refer to as |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2019 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 1, 2019 |
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 • Continued Progress with VK0214 for X-ALD; Expect to Commence Phase 1 Clinical Study in 1H20 SAN DIEGO, August 1, 2019 - Viki |
|
| August 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| July 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2019 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 2, 2019 |
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors Exhibit 99.1 Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors SAN DIEGO, CA – July 2, 2019 – Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Kathy Rouan, Ph.D., to its board of directors. With nearly 30 years o |
|
| May 23, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2019 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 2, 2019 |
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily • Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Expected to Commence in 2H19 • IND Filing for VK0214 in X-ALD |
|
| May 2, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2019 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THE |
|
| April 5, 2019 |
VKTX / Viking Therapeutics, Inc. DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 5, 2019 |
our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 5, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 13, 2019 |
VKTX / Viking Therapeutics, Inc. S-8 As filed with the Securities and Exchange Commission on March 13, 2019 Registration No. |
|
| March 13, 2019 |
EX-99.1 2 vktx-ex9916.htm EX-99.1 Exhibit 99.1 Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Additional VK2809 Phase 2 Data to be Presented at EASL 2019; Results Demonstrate Promising Efficacy at Doses as Low as 5 mg Daily • Initiation of Phase 2b Study of VK2809 in Biopsy-Confirmed NA |
|
| March 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2019 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 13, 2019 |
Non-Employee Director Compensation Policy. Exhibit 10.15 Viking Therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each non-employee member of the board of directors (the “Board”) of Viking Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation for his or her service on the Board as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation d |
|
| March 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeu |
|
| March 13, 2019 |
Exhibit 10.14 EMPLOYMENT AGREEMENT Employee agrees to the terms and conditions of employment with Viking Therapeutics, Inc. (“Company”) set forth in this restated Employment Agreement (“Agreement”), effective as of June 2, 2014 (“Effective Date”). 1.Employment Terms. (a)Employment Period. The Company shall employ Employee, and Employee hereby accepts employment with the Company, upon the terms and |
|
| February 14, 2019 |
VKTX / Viking Therapeutics, Inc. / Arrowpoint Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2019 |
VKTX / Viking Therapeutics, Inc. / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VIKING THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 92686J106 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 13, 2019 |
VKTX / Viking Therapeutics, Inc. / SPHERA FUNDS MANAGEMENT LTD. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Viking Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 13, 2018 |
VKTX / Viking Therapeutics, Inc. / LIGAND PHARMACEUTICALS INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* VIKING THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 92686J106 (CUSIP Number) Ligand Pharmaceuticals Incorporated 3911 Sorrento Valley Boulevard, Suite 110 San Diego, CA 92121 (858) |
|
| November 13, 2018 |
TRADING PLAN (SEC Rule 10b5-1) EX-99.13 Exhibit 99.13 TRADING PLAN (SEC Rule 10b5-1) This Trading Plan is entered into as of September 28, 2018 (the “Signing Date”) between Ligand Pharmaceuticals Incorporated (“Client”) and Roth Capital Partners, LLC (“Broker”). WHEREAS, Client wishes to establish this Trading Plan to sell or purchase shares of VKTX (“Stock”) of Viking Therapeutics, Inc. (“Issuer”) from Account Number (the “Acc |
|
| November 7, 2018 |
Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Announced Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol (LDL-C) • Presented Positive Results from Phase 2 Study of VK5211 in Patients Recovering |
|
| November 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2018 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2018 |
EX-10.1 2 vktx-ex10180.htm EX-10.1 Exhibit 10.1 EXTENSION OF TERM AND AMENDMENT OF SUBLEASE This Extension of Term and Amendment of Sublease (the “Agreement”), dated as of the 30th day of September, 2018, between Fish & Richardson P.C., a Massachusetts corporation, with its principal office at One Marina Park Drive, Boston, Massachusetts 02210 (“Sublandlord”) and Viking Therapeutics, Inc., a Delaw |
|
| November 7, 2018 |
VKTX / Viking Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING |
|
| September 21, 2018 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-226133 PROSPECTUS SUPPLEMENT (To Prospectus dated July 19, 2018) 9,500,000 Shares Common Stock We are offering 9,500,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market under the symbol “VKTX.” On September 20, 2018, the closing price of our common stock on the Nasdaq Capital Market was $18.9 |
|
| September 21, 2018 |
EX-1.1 2 vktx-ex1164.htm EX-1.1 Exhibit 1.1 9,500,000 Shares1 Viking therapeutics, Inc. Common Stock, $0.00001 par value per share UNDERWRITING AGREEMENT September 20, 2018 William Blair & Company, L.L.C. As Representative of the several Underwriters named in Schedule I hereto c/o William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Viking Therapeuti |
|
| September 21, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2018 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 21, 2018 |
Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock Exhibit 99.1 Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock SAN DIEGO, CA – September 20, 2018 – Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 9,500,000 shares of its com |
|
| September 19, 2018 |
Subject to Completion, Dated September 19, 2018 Filed pursuant to Rule 424(b)(5) Registration No. 333-226133 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we |
|
| September 18, 2018 |
Exhibit 99.1 Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients Receiving VK2809 57% to 60% Median Liver Fat Reduction Observed in VK2809-Treated Patients 77% to 91% of VK28 |
|
| September 18, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 18, 2018 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2018 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 9, 2018 |
Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 vktx-ex9916.htm EX-99.1 Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment complete for VK2809 Phase 2 fatty liver and hypercholesterolemia study, results expected 2H18 • Final results from Phase 2 VK5211 study for hip fracture selected for presentation at plenary sessi |
|
| August 9, 2018 |
Office Lease, dated May 25, 2018, by and between Viking Therapeutics, Inc. and Kilroy Realty, L.P. Exhibit 10.1 DEL MAR CORPORATE CENTRE II OFFICE LEASE This Office Lease (this "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and VIKING THERAPEUTICS, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEA |
|
| August 9, 2018 |
Exhibit 12.1 Viking Therapeutics, Inc. Statement Regarding the Computation of Ratio of Earnings to Fixed Charges The following table sets forth our ratio of earnings to fixed charges for the years ended December 31, 2013, 2014, 2015, 2016, and 2017, and the six months ended June 30, 2018. As the ratios of earnings to fixed charges indicate less than one-to-one coverage for each of the periods pres |
|
| August 9, 2018 |
VKTX / Viking Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THER |
|
| July 17, 2018 |
VKTX / Viking Therapeutics, Inc. CORRESP 12340 El Camino Real, Suite 250 San Diego, CA 92130 July 17, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance Attention: Abigail Jacobs or Erin Jaskot 100 F Street, N. |
|
| July 11, 2018 |
VKTX / Viking Therapeutics, Inc. FORM S-3 As filed with the Securities and Exchange Commission on July 11, 2018 Registration No. |
|
| July 11, 2018 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.10 VIKING THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities Table of Contents Page Article 1 DEFINITIONS1 Section 1.01 Definitions of Terms1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES5 Section 2.01 Designation and Terms of Securities5 Section 2.02 Form of Securities and Trustee’s Certificate8 Section |
|
| July 11, 2018 |
Exhibit 12.1 Viking Therapeutics, Inc. Statement Regarding the Computation of Ratio of Earnings to Fixed Charges The following table sets forth our ratio of earnings to fixed charges for the years ended December 31, 2013, 2014, 2015, 2016, and 2017, and the three months ended March 31, 2018. As the ratios of earnings to fixed charges indicate less than one-to-one coverage for each of the periods p |
|
| June 12, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2018 Viking Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37355 46-1073877 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 12, 2018 |
Viking Therapeutics Announces Closing of Public Offering of Common Stock Exhibit 99.1 Viking Therapeutics Announces Closing of Public Offering of Common Stock SAN DIEGO, CA – June 12, 2018 – Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 8,625,000 sha |
|
| June 7, 2018 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-212134 Registration No. 333-225479 PROSPECTUS SUPPLEMENT (To Prospectus dated July 26, 2016) 7,500,000 Shares Common Stock We are offering 7,500,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market under the symbol “VKTX.” On June 6, 2018, the closing price of our common stock on the Nasdaq Ca |
